Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Average Rating of “Moderate Buy” from Analysts

Bicara Therapeutics Inc. (NASDAQ:BCAX) has earned a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $28.3344.

A number of research firms recently commented on BCAX. BTIG Research reiterated a “buy” rating on shares of Bicara Therapeutics in a research note on Thursday, January 15th. Citigroup initiated coverage on Bicara Therapeutics in a research report on Thursday, January 29th. They issued an “outperform” rating for the company. Wedbush reiterated an “outperform” rating and issued a $30.00 price target on shares of Bicara Therapeutics in a report on Tuesday, January 13th. Mizuho upgraded Bicara Therapeutics to a “hold” rating in a research note on Thursday, December 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Friday, January 9th.

Insider Buying and Selling at Bicara Therapeutics

In other Bicara Therapeutics news, COO Ryan Cohlhepp sold 12,500 shares of the firm’s stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $18.05, for a total value of $225,625.00. Following the transaction, the chief operating officer owned 193,641 shares of the company’s stock, valued at $3,495,220.05. This trade represents a 6.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Claire Mazumdar sold 41,163 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $18.86, for a total value of $776,334.18. Following the transaction, the chief executive officer directly owned 309,892 shares of the company’s stock, valued at $5,844,563.12. This trade represents a 11.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 95,922 shares of company stock valued at $1,784,142. Corporate insiders own 15.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BCAX. Legal & General Group Plc increased its position in Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after buying an additional 1,233 shares during the period. Ameritas Investment Partners Inc. grew its position in shares of Bicara Therapeutics by 73.0% during the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after acquiring an additional 1,474 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Bicara Therapeutics by 13.2% in the 2nd quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock worth $157,000 after acquiring an additional 1,962 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in Bicara Therapeutics in the 4th quarter valued at about $45,000. Finally, Avanza Fonder AB lifted its position in Bicara Therapeutics by 42.7% in the 3rd quarter. Avanza Fonder AB now owns 9,371 shares of the company’s stock valued at $148,000 after purchasing an additional 2,804 shares during the last quarter.

Bicara Therapeutics Trading Down 7.8%

Bicara Therapeutics stock opened at $15.10 on Friday. Bicara Therapeutics has a 52 week low of $7.80 and a 52 week high of $19.71. The stock has a market cap of $827.21 million, a P/E ratio of -6.74 and a beta of -0.79. The stock has a 50 day moving average of $17.31 and a 200-day moving average of $15.04.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.12). As a group, equities analysts predict that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.